Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 10/20 | 0.73 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.73 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.73 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172174 | 0.94 | S1PR1 (0.78) | S1PR1S1PR4S1PR5THRATHRB | |
| SCHEMBL2954054 | 0.94 | S1PR1 (0.78) | S1PR1S1PR4S1PR5THRATHRB | |
| SCHEMBL2955490 | 0.94 | S1PR1 (0.78) | S1PR1S1PR4S1PR5THRATHRB | |
| SCHEMBL2955337 | 0.94 | S1PR1 (0.78) | S1PR1S1PR4S1PR5THRATHRB | |
| SCHEMBL2955485 | 0.94 | S1PR1 (0.78) | S1PR1S1PR4S1PR5THRATHRB | |
| SCHEMBL2954058 | 0.94 | S1PR1 (0.78) | S1PR1S1PR4S1PR5THRATHRB | |
| SCHEMBL13237848 | 0.90 | S1PR1 (0.75) | S1PR1S1PR4S1PR5THRATHRB | |
| SCHEMBL3172869 | 0.89 | S1PR1 (0.70) | S1PR1S1PR4S1PR5THRATHRB | |
| SCHEMBL3172852 | 0.89 | S1PR1 (0.70) | S1PR1S1PR4S1PR5THRATHRB | |
| SCHEMBL3177366 | 0.88 | S1PR1 (0.69) | S1PR1S1PR4S1PR5THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | claimed |
| EP-3723801-B9 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | BIORA THERAPEUTICS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3723801-B1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | BIORA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | GLAS USA LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | S1PR2, S1PR1, S1PR4 | S1PR1 2/4885S1PR4 3/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.